Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.

about

An angiotensin-converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin-pathway medications on posttraumatic stress symptoms.Mutations in folate transporter genes and risk for human myelomeningocele

P2860

Q39013181-61AB7554-2EEE-4600-8059-FABEC69EBBD1 Q59192480-CEF5E306-5088-4564-9966-DC485E9282DE

P2860

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.

Item

http://www.wikidata.org/entity/Q50648690

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@en

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@nl

type

Item

label

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@en

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@nl

prefLabel

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@en

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@nl

P1476

Pharmacogenetics of pemetrexed ...... s novel toxicity associations.

@en

P2093

A Corrigan

http://www.w3.org/2001/XMLSchema#string

A M Marinaki

http://www.w3.org/2001/XMLSchema#string

J D Sanderson

http://www.w3.org/2001/XMLSchema#string

J L Walker

http://www.w3.org/2001/XMLSchema#string

M A Hernandez

http://www.w3.org/2001/XMLSchema#string

S Wickramasinghe

http://www.w3.org/2001/XMLSchema#string

P2860

Population structure and eigenanalysis

Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption

Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity

Pharmacogenomics knowledge for personalized medicine

PLINK: a tool set for whole-genome association and population-based linkage analyses

Principal components analysis corrects for stratification in genome-wide association studies

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

P2888

tpj.2014.13

P304

411-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/TPJ.2014.13

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037405778

http://www.w3.org/2001/XMLSchema#string

P698

24732178

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.

about

P2860

P2860

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698